Taken together, these findings suggest that PAI-1 may serve as a marker of GBM tumor progression and specifically, PAI-1 could be a cellular response to lucanthone treatment as a mechanism of survival against autophagy inhibition. The gene discussed is SERPINE1; the disease is neoplasm.